Singapore: A study by Janssen Research and Development revealed that patients with active psoriatic arthritis, who were treated using Centocor's STELARA (ustekinumab), witnessed substantial improvements in signs and symptoms of the disease.

Data from the 615-patient phase III trial, which was presented at the European League Against Rheumatism (EULAR) Annual Congress, highlighted that patients who received STELARA 45 mg and 90 mg achieved the primary endpoint of the study, a significant reduction in arthritis signs and symptoms at week 24.

STELARA, a interleukin (IL)-12/23 inhibitor, also led to significant improvements in physical function, including dactylitis and enthesitis, which are the two common manifestations of psoriatic arthritis casusing pain and swelling.

STELARA is currently being investigated in a phase III program for the treatment of active psoriatic arthritis and is approved for the treatment of moderate-to-severe plaque psoriasis in 65 countries. The EULAR press committee selected the STELARA psoriatic arthritis study findings to be presented during the official EULAR press conference on Friday, June 8, 2012.

Dr Iain B McInnes, professor, University of Glasgow, and a study investigator, said that, "Some 15 percent of patients living with psoriasis of the skin will develop psoriatic arthritis. This is a challenging disease that causes great distress for those afflicted, for which we currently have too few treatment options. We look forward to additional data from the phase III psoriatic arthritis clinical development program to allow us to more fully assess the efficacy and safety of STELARA in the treatment of this complex inflammatory disease."